Towards Healthcare Research & Consulting

Acid Citrate Dextrose (ACD) Tubes Market Size, Share, Forecast (2026-2035), ACD-A and ACD-B Blood Collection Tubes for Blood Banking, PRP, HLA Typing, Paternity and Molecular Testing

The acid citrate dextrose (ACD) tubes market is estimated at USD 329.47 million in 2026 and is projected to reach USD 538.01 million by 2035, expanding at a CAGR of 5.60% from 2026 to 2035. The acid citrate dextrose (ACD) tubes market was valued at USD 312.00 million in 2025, the base year. The acid citrate dextrose (ACD) tubes market covers evacuated and non-evacuated blood collection tubes containing acid citrate dextrose anticoagulant, including ACD-A and ACD-B solution tubes, made from glass and plastic, used for blood banking and transfusion testing, HLA typing and paternity testing, platelet-rich plasma (PRP) preparation, cell preservation and molecular testing by hospitals, blood banks, diagnostic and reference laboratories, and clinics. ACD-A Tubes accounted for the largest type share in 2025, at 63.00%, because they are standard for PRP preparation, cell studies, and many reference lab tests.

Last updated 16 November 2026   |   Primary source: Towards Healthcare   |   Report: 7191   |   Derived values are labelled
USD 329.47 Mn
Revenue, 2026
USD 538.01 Mn
Forecast, 2035
5.60%
CAGR, 2026-2035
Global
Report Coverage

Key Takeaways

Acid Citrate Dextrose (ACD) Tubes Market Snapshot, Comparison and Top Companies

Market Size & Growth Outlook

  • Market size in 2025: USD 312.00 million
  • Estimated market size in 2026: USD 329.47 million
  • Projected market size by 2035: USD 538.01 million
  • CAGR (2026-2035): 5.60%

Regional Market Spotlight

  • North America led the market with a 38.00% share in 2025.
  • Europe accounted for 27.00% of the market in 2025.
  • Asia Pacific accounted for 26.00% of the market in 2025 and is projected to be the fastest-growing region, at a CAGR of 6.62% from 2026 to 2035.

Segmental Spotlight

  • ACD-A Tubes represented the leading product type, contributing 63.00% of the market in 2025.
  • Plastic (PET) emerged as the dominant material, accounting for 71.00% of the market in 2025.
  • Blood Banking & Transfusion led the largest application segment, with a 28.00% share in 2025.
  • Hospitals accounted for the highest end-user share at 34.00% in 2025.

The acid citrate dextrose (ACD) tubes market is projected to grow from USD 312.00 million in 2025 to USD 538.01 million by 2035 because ACD tubes preserve cells and platelets better than many other additives, making them essential for HLA, blood bank, and PRP work. Transplant testing, PRP adoption, blood banking, and molecular testing support steady growth, lifting the market to USD 409.71 million by 2030 and sustaining a CAGR of 5.60% from 2026 to 2035.

Acid Citrate Dextrose (ACD) Tubes Market Size is USD 329.47 Million in 2026.

Analyst View: We estimated the market using ACD tube volumes across different applications and regions, along with average selling prices. These estimates were cross-checked against the reported revenues of blood collection tube manufacturers to assess their reliability. Since published data specifically covering ACD tubes is limited, the market estimate was developed using available industry evidence and underlying demand indicators.

  • PRP growth in orthopaedics and aesthetics.
  • Plastic tubes replacing glass.
  • Pre-analytical quality standards.
  • Transplant and HLA testing growth.
  • Cell therapy sample collection.
  • Automation-friendly tube labelling.

Acid Citrate Dextrose (ACD) Tubes Market Drivers, Restraints and Opportunities

Market Drivers - Impact & CAGR Contribution (2026-2035)

Driver Impact ≈ CAGR Contribution Time Horizon Key Regions
Transplant testing grows High +2.19 pp Short to long term Global, strongest in North America
PRP use expands Medium +1.84 pp Medium to long term Global, fastest uptake in Asia Pacific
Blood bank activity continues Medium +1.57 pp Short to medium term Global
Molecular testing needs stable samples Low +1.23 pp Long term Developed and emerging markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Taken together, these drivers add about 6.83 percentage points to the annual growth of the acid citrate dextrose (ACD) tubes market, with transplant testing growth having the largest effect. Their influence is strongest in North America, while uptake grows fastest in Asia Pacific.

Market Restraints - Impact & Negative CAGR Contribution (2026-2035)

Restraint Impact ≈ Negative CAGR Contribution Time Horizon Key Regions
Price pressure High -0.55 pp Short to medium term Global
Substitution by other anticoagulants High -0.41 pp Medium term Price-sensitive and emerging markets
Tube shortages in supply disruptions Medium -0.27 pp Short term North America and other mature markets

Note: Contributions are indicative estimates of each factor's effect on annual growth.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

These restraints are expected to reduce annual growth of the acid citrate dextrose (ACD) tubes market by about 1.23 percentage points, led by price pressure. Their effect eases over the forecast period as suppliers, buyers, and regulators adapt, leaving a net CAGR of 5.60% from 2026 to 2035.

Market Opportunity

Growing demand for platelet-rich plasma (PRP) kits and the expansion of laboratory facilities across Asia are creating new growth opportunities for the ACD tube market. Increasing cell therapy activities are also driving demand for specialized sample collection solutions. Additionally, the rising adoption of specialized molecular tests and the expansion of private-label manufacturing and supply are expected to support market growth.

Market Segmentation: 2025 Share and Value

Acid Citrate Dextrose (ACD) Tubes Market by Type 2025 Share

Acid Citrate Dextrose (ACD) Tubes Market Segment Dominates by 63% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

ACD-A Tubes represented 63.00% of the acid citrate dextrose (ACD) tubes market in 2025 and is projected to expand at a CAGR of 5.82% from 2026 to 2035. ACD-A tubes lead because they are standard for PRP preparation, cell studies, and many reference lab tests. The ACD-A Tubes segment is expected to grow broadly in line with the overall market over the forecast period.

ACD-B Tubes are used for HLA typing, paternity, and blood bank studies. The ACD-B Tubes segment is expected to grow slower than the overall market over the forecast period.

Segment Outlook: strengthening its lead in the acid citrate dextrose (ACD) tubes market.

Acid Citrate Dextrose (ACD) Tubes Market by Material 2025 Share

Acid Citrate Dextrose (ACD) Tubes Market Segment Dominates by 71% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

The plastic (PET) segment represented 71.00% of the acid citrate dextrose (ACD) tubes market in 2025 and is projected to expand at a CAGR of 5.83% from 2026 to 2035. Plastic tubes lead and grow fastest because they are shatter-resistant and lighter to ship. The plastic (pet) segment is expected to grow broadly in line with the overall market over the forecast period.

The glass tubes remain in some specialised testing. The glass segment is expected to grow slower than the overall market over the forecast period.

Segment Outlook: Plastic (PET) remains the largest material segment through 2035, holding about 72.54% of the market in 2035, and also records the highest CAGR of 5.83% from 2026 to 2035, strengthening its lead in the acid citrate dextrose (ACD) tubes market.

Acid Citrate Dextrose (ACD) Tubes Market by Application 2025 Share

Acid Citrate Dextrose (ACD) Tubes Market Segment Dominates by 28% in 2025

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Blood Banking & Transfusion: This segment accounted for 28.00% of the acid citrate dextrose (ACD) tubes market in 2025 and is projected to expand at a CAGR of 4.79% from 2026 to 2035. Blood banking and transfusion testing lead because ACD preserves red cells and platelets. The blood banking & transfusion segment is expected to grow slower than the overall market over the forecast period.

HLA Typing & Paternity: HLA typing and paternity testing use ACD to preserve white cells. The HLA Typing & Paternity segment is expected to grow slower than the overall market over the forecast period.

Platelet-Rich Plasma (PRP): PRP grows fastest with orthopaedic, sports medicine, and aesthetic use. The platelet-rich plasma (prp) segment is expected to grow faster than the overall market over the forecast period.

Molecular & Cell-Based Testing: Molecular and cell-based testing uses ACD for DNA and flow cytometry samples. The molecular & cell-based testing segment is expected to grow slower than the overall market over the forecast period.

Others:  uses include research. The other segments are expected to grow slower than the overall market over the forecast period.

Segment Outlook: Blood Banking & Transfusion remains the largest application segment through 2035, holding about 25.93% of the market in 2035, while Platelet-Rich Plasma (PRP) records the highest CAGR of 7.19% from 2026 to 2035. Others hold the smallest share today and serve more specialised needs within the acid citrate dextrose (ACD) tubes market.

Acid Citrate Dextrose (ACD) Tubes Market by End User 2025 Share

Acid Citrate Dextrose (ACD) Tubes Market Segment Dominates by 34% in 2025.

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Towards Healthcare database, and Towards Healthcare analysts.

Hospitals segment accounted for 34.00% of the acid citrate dextrose (ACD) tubes market in 2025 and is projected to expand at a CAGR of 5.05% from 2026 to 2035. Hospitals lead because they draw most blood samples. The hospitals segment is expected to grow slower than the overall market over the forecast period.

Blood Banks use ACD for donor and transfusion testing. The blood banks segment is expected to grow broadly in line with the overall market over the forecast period.

Diagnostic & Reference Labs Diagnostic and reference labs run HLA, paternity, and molecular tests. The diagnostic & reference labs segment is expected to grow broadly in line with the overall market over the study period.

Clinics & Others including orthopaedic and aesthetic clinics, grow fastest for PRP. The clinics & others segment is expected to grow faster than the overall market over the forecast period.

Segment Outlook: Hospitals remain the largest end user segment through 2035, holding about 32.26% of the market in 2035, while Clinics & Others records the highest CAGR of 6.95% from 2026 to 2035. Although Clinics & Others starts from the smallest base, its faster growth shows how demand is shifting within the acid citrate dextrose (ACD) tubes market.

Analyst View: Market shares across segments were estimated based on demand patterns, product portfolios, and pricing within each category. ACD-A tubes, plastic (PET) tubes, blood banking and transfusion, and hospitals currently hold the leading positions in their respective categories, reflecting their alignment with the primary requirements of end users. Meanwhile, platelet-rich plasma (PRP) applications and clinics and other healthcare settings are expected to gain market share as newer technologies, user groups, and applications expand at a faster pace.

Regional Analysis

Acid Citrate Dextrose (ACD) Tubes Market Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Acid Citrate Dextrose (ACD) Tubes Market by Region 2025 Share

Note: 2025 is the base year; 2035 shares and CAGRs are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

North America accounted for 38.00% of the acid citrate dextrose (ACD) tubes market in 2025 and is projected to expand at a CAGR of 5.02% from 2026 to 2035. North America leads because of high specialty testing volumes, transplant programmes, and widespread PRP use. North America is expected to grow slower than the overall market between 2026 and 2035.

Europe has strong blood bank and HLA testing networks. Europe is expected to grow broadly in line with the overall market between 2026 and 2035.

Asia Pacific grows fastest with expanding laboratories, transplant centres, and aesthetic clinics in China, India, and Korea. Asia Pacific is expected to grow faster than the overall market between 2026 and 2035.

Latin America has growing PRP and lab demand. Latin America is expected to grow broadly in line with the overall market between 2026 and 2035.

Middle East & Africa have expanding transplant and lab services. Middle East & Africa is expected to grow broadly in line with the overall market between 2026 and 2035.

Analyst View: Regional shares were built from demand, installed base, spending and supplier presence in each region. North America leads because of its mature demand base and strong suppliers. We assign Asia Pacific the highest growth premium because investment, adoption, and capacity are expanding fastest there.

Competitive Landscape

Acid Citrate Dextrose (ACD) Tubes Market Companies are Becton, Dickinson and Company, Greiner Bio-One, Sarstedt, Terumo, Sekisui Medical, Improve Medical, Weihai Hongyu, Nipro, FL Medical, Narang Medical

Top 10 Companies in the Acid Citrate Dextrose (ACD) Tubes Market, 2025

Rank Company Name 2025 Share (%) Key Products / Business Headquarters
1 Becton, Dickinson and Company 12.18% BD Vacutainer ACD-A and ACD-B tubes United States
2 Greiner Bio-One 4.81% VACUETTE ACD tubes Austria
3 Sarstedt 2.56% S-Monovette citrate and ACD tubes Germany
4 Terumo 1.60% Venoject blood collection tubes Japan
5 Sekisui Medical 1.60% INSEPACK blood collection tubes Japan
6 Improve Medical 1.28% Vacuum blood collection tubes China
7 Weihai Hongyu 0.96% Blood collection tubes China
8 Nipro 0.64% Vacuum blood collection tubes Japan
9 FL Medical 0.64% Blood collection tubes Italy
10 Narang Medical 0.64% Blood collection tubes India

Note: Company shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Becton, Dickinson and Company led the acid citrate dextrose (ACD) tubes market with an estimated 12.18% share of 2025 revenue, followed by Greiner Bio-One at 4.81% share and Sarstedt at 2.56% share. Becton, Dickinson and Company leads with BD Vacutainer ACD-A and ACD-B tubes, Greiner Bio-One competes with VACUETTE ACD tubes, and Sarstedt offers s-Monovette citrate and ACD tubes. Terumo, Sekisui Medical, Improve Medical, Weihai Hongyu, Nipro, FL Medical, and Narang Medical compete through venoject blood collection tubes, INSEPACK blood collection tubes, vacuum blood collection tubes, blood collection tubes, vacuum blood collection tubes, blood collection tubes, and blood collection tubes.

The top 10 companies accounted for an estimated 26.92% of 2025 revenue, while the remaining 73.08% was shared among many regional tube makers and PRP kit suppliers. The acid citrate dextrose (ACD) tubes market is concentrated among a few large blood collection suppliers, and competition centres on additive accuracy, draw volume consistency, sterility, regulatory clearances, lab system compatibility and price.

Company Snapshots

Becton, Dickinson and Company: Becton, Dickinson and Company is headquartered in the United States. It held an estimated 12.18% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on BD Vacutainer ACD-A and ACD-B tubes. In the Towards Healthcare Companies Quadrant it is classified as a Leader.

Greiner Bio-One: Greiner Bio-One is headquartered in Austria. It held an estimated 4.81% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on VACUETTE ACD tubes. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Sarstedt: Sarstedt is headquartered in Germany. It held an estimated 2.56% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on S-Monovette citrate and ACD tubes. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Terumo: Terumo is headquartered in Japan. It held an estimated 1.60% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on Venoject blood collection tubes. In the Towards Healthcare Companies Quadrant it is classified as a Leader.

Sekisui Medical: Sekisui Medical is headquartered in Japan. It held an estimated 1.60% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on INSEPACK blood collection tubes. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Improve Medical: Improve Medical, part of Guangzhou Improve Medical Instruments Co., Ltd., is headquartered in China. It held an estimated 1.28% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on Vacuum blood collection tubes. In the Towards Healthcare Companies Quadrant it is positioned as a Leader.

Weihai Hongyu: Weihai Hongyu is headquartered in China. It held an estimated 0.96% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on Blood collection tubes. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Nipro: Nipro is headquartered in Japan. It held an estimated 0.64% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on Vacuum blood collection tubes. In the Towards Healthcare Companies Quadrant it is classified as an Innovator.

FL Medical: FL Medical is headquartered in Italy. It held an estimated 0.64% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on Blood collection tubes. In the Towards Healthcare Companies Quadrant it is positioned as an Innovator.

Narang Medical: Narang Medical is headquartered in India. It held an estimated 0.64% share of the acid citrate dextrose (ACD) tubes market in 2025. Its offering centres on Blood collection tubes. In the Towards Healthcare Companies Quadrant it is classified as an Innovator.

Companies Ecosystem

The acid citrate dextrose (ACD) tubes ecosystem links material suppliers, tube makers, distributors, users and regulators, with each stage adding value before products reach end users.

Ecosystem Stage Role in the Market Key Companies
Material Suppliers Supply PET, glass, stoppers and anticoagulants Resin, glass and chemical suppliers
Tube Makers Make and sterilise ACD tubes BD, Greiner Bio-One, Sarstedt, Terumo
Distributors Supply labs and clinics Medline, Cardinal Health, Fisher Scientific
Users Collect and test samples Hospitals, blood banks, reference labs, PRP clinics
Regulators Clear devices FDA, EU IVDR, CLSI standards

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Material Suppliers: Supply PET, glass, stoppers, and anticoagulants. Key participants include Resin, glass, and chemical suppliers.

Tube Makers: Make and sterilise ACD tubes. Key participants include BD, Greiner Bio-One, Sarstedt, and Terumo.

Distributors: Supply labs and clinics. Key participants include Medline, Cardinal Health, Fisher Scientific.

Users: Collect and test samples. Key participants include Hospitals, blood banks, reference labs, and PRP clinics.

Regulators: Clear devices. Key participants include FDA, EU IVDR, CLSI standards.

Value in the acid citrate dextrose (ACD) tubes market flows from upstream material and technology suppliers to manufacturers and service providers, then through distribution partners to end users. Companies that integrate several stages or build long-term relationships with end users capture a larger share of this value.

Towards Healthcare Companies Quadrant

The Towards Healthcare Companies Quadrant positions key participants in the acid citrate dextrose (ACD) tubes market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity, and partnerships. Positions reflect each company's estimated 2025 share of the acid citrate dextrose (ACD) tubes market and our assessment of its product innovation, portfolio breadth, and partnerships.

Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.

Leaders: Becton, Dickinson and Company, Greiner Bio-One, Sarstedt, Terumo, Sekisui Medical and Improve Medical combine high market share with broad portfolios and strong innovation.

Innovators: Weihai Hongyu, Nipro, FL Medical and Narang Medical bring newer technologies and specialised products.

Recent Developments

  • In February 2026, BD completed the combination of its Biosciences and Diagnostic Solutions businesses with Waters Corporation, leaving BD focused on its core medical technology businesses, which include specimen collection.

Market Segments

By Type

  • ACD-A Tubes
  • ACD-B Tubes

By Material

  • Plastic (PET)
  • Glass

By Application

  • Blood Banking & Transfusion
  • HLA Typing & Paternity
  • Platelet-Rich Plasma (PRP)
  • Molecular & Cell-Based Testing
  • Others

By End User

  • Hospitals
  • Blood Banks
  • Diagnostic & Reference Labs
  • Clinics & Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of MEA

Research Methodology

The acid citrate dextrose (ACD) tubes market was defined as evacuated and non-evacuated blood collection tubes containing acid citrate dextrose anticoagulant, including ACD-A and ACD-B solution tubes, made from glass and plastic, used for blood banking and transfusion testing, HLA typing and paternity testing, platelet-rich plasma (PRP) preparation, cell preservation and molecular testing by hospitals, blood banks, diagnostic and reference laboratories, and clinics. The 2025 base year was built bottom-up from demand volumes and average prices by type, material, application and end user and region, and checked top-down against the market-specific revenues of leading companies and published estimates.

Segment, regional and company values were allocated from type, material, application and end user and region demand. Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: The acid citrate dextrose (ACD) tubes market is set for steady expansion as transplant testing and related demand keep growing. Our estimate links value to underlying demand, installed base and pricing, so the forecast follows real adoption rather than headline hype. The main upside comes from PRP kits and Asian laboratory growth, while the main risks are price pressure and anticoagulant substitution.

References

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar